PeptideDeepDive
KPV Peptide: Evidence, Safety & Legal Status
KPV is a three-amino-acid peptide fragment studied mainly in preclinical inflammation, gut and skin models. Human treatment evidence remains absent, so this guide separates laboratory findings from what is actually known about safety, FDA status and UK/EU regulation.
KPV (lysine-proline-valine) is a three-amino-acid peptide fragment of α-melanocyte-stimulating hormone studied for anti-inflammatory effects. Most evidence comes from cell and animal models involving intestinal or skin inflammation. FDA’s 2026 review found no human clinical studies or human exposure data for KPV, and KPV is not an FDA-approved medicine.
Het redactieteam van PeptideDeepDive checks evidence claims against primary literature and regulatory claims against FDA, MHRA, HPRA and EU legal sources. We have not added a medical reviewer credential because no verified clinician reviewer was provided. This page is educational only and does not provide dosing, treatment or legal advice.
What Is KPV Peptide?
KPV (lysine-proline-valine) is the C-terminal tripeptide fragment of α-melanocyte-stimulating hormone (α-MSH). Researchers mainly study it for anti-inflammatory effects in intestinal, immune-cell and skin models. However, interest around KPV and ulcerative-colitis-like inflammation comes from laboratory and animal work, not from controlled human treatment trials. For broader recovery-peptide context, compare the evidence with BPC-157 en TB-500 .
The FDA has not approved KPV for any use, and FDA’s 2026 briefing document says that neither KPV free base nor KPV acetate is a component of an FDA-approved drug. Meanwhile, in the UK and EU, the key regulatory issue is different: KPV does not hold a standard medicine marketing authorisation. Therefore, rules on unlicensed supply, import and possession can differ by jurisdiction.
How KPV Is Thought to Work
Preclinical studies suggest that KPV can affect inflammatory signalling, including NF-κB-related pathways, and can enter certain intestinal and immune cells through the PepT1 transporter. For example, a 2008 Gastroenterology study found reduced inflammatory signalling in human cell lines and reduced colitis measures in mouse models. Even so, those findings do not show that KPV treats inflammatory bowel disease or skin disease in people.
What Does the KPV Peptide Evidence Show?
Human clinical evidence is not just limited; FDA’s 2026 evaluation says it did not identify clinical studies or human exposure data for KPV free base or KPV acetate by any route. Instead, the evidence base includes cell studies, animal inflammation models and a human-cadaver-skin delivery study. In the gut literature, KPV has reduced inflammatory signals and colitis measures in experimental models. However, researchers have not established controlled human efficacy.
FDA also reported that it did not identify human pharmacokinetic, pharmacodynamic or exposure studies for KPV. As a result, clinical trials have not established validated human dosing or long-term human safety. Accordingly, this article does not provide dosing guidance.
KPV FDA Status in 2026: Approval, 503A & Safety Gaps
KPV had no FDA drug approval and no applicable USP/NF drug-substance monograph. Originally, sponsors withdrew the bulk-substance nomination. Nevertheless, FDA chose to evaluate KPV free base and KPV acetate on its own initiative.
FDA’s Pharmacy Compounding Advisory Committee discussed KPV-related bulk substances for possible inclusion on the 503A Bulks List. Specifically, FDA evaluated wound healing and inflammatory conditions. Ultimately, the agency’s briefing document said the evaluation criteria weighed against adding KPV free base or KPV acetate to the list. Even so, advisory-committee input is non-binding, and FDA still has to complete its own rulemaking process.
KPV is not FDA-approved. FDA’s 2026 KPV briefing found no applicable USP/NF drug-substance monograph, no FDA-approved drug containing KPV free base or acetate, no human clinical studies, and insufficient effectiveness and safety information for the proposed compounded uses. FDA staff concluded that the available criteria weighed against adding KPV free base or KPV acetate to the 503A Bulks List. Read the FDA KPV briefing document.
FDA’s current compounding-safety page also states that it has not identified human exposure data for drug products containing KPV by any route and therefore lacks important information needed to determine whether KPV could cause harm in people. That is different from preclinical anti-inflammatory findings.
Is KPV Legal in the UK, Ireland, Germany & EU?
KPV does not have the kind of standard medicine marketing authorisation that approved medicines hold in the UK or EU. However, that fact does not create one simple Europe-wide answer about possession or import. Instead, national rules on unlicensed medicinal products, supply and customs can differ. Therefore, the summaries below focus on medicine-authorisation status and do not provide legal advice.
🇬🇧 United Kingdom MHRA
KPV is not a UK-licensed medicine. However, the MHRA allows limited regulated supply of certain unlicensed medicines when a prescriber identifies a special clinical need for an individual patient. That “specials” route does not amount to general KPV approval or permit unrestricted consumer marketing. See the MHRA guidance on unlicensed medicines .
🇮🇪 Ireland HPRA
KPV does not appear as a standard authorised human medicine in the regulatory framework used by HPRA. Irish medicine supply and import rules can differ from simple product-authorisation status, so readers should check current HPRA guidance for a specific situation.
🇩🇪 Germany EU / National Rules
There is no standard EU marketing authorisation for KPV as a medicine. Germany also applies national medicines law to manufacture, supply and import, so the absence of marketing authorisation should not be reduced to a simple “legal/illegal” label.
🇪🇺 European Union Directive 2001/83/EC
EU medicines law generally requires a marketing authorisation before a medicinal product is placed on a member-state market, subject to defined exceptions in national law. KPV has no standard EU medicine authorisation discussed in the sources used for this guide.
The sources reviewed for this guide did not identify a standard EU marketing authorisation for KPV. Likewise, KPV is not a UK-licensed medicine. For that reason, anyone facing a real-world import or supply question should check current regulator guidance and obtain local legal advice rather than relying on a simple “legal” or “illegal” label.
KPV vs BPC-157 & TB-500: How They Compare
| Peptide | Primary research focus | Human evidence | 2026 regulatory note |
|---|---|---|---|
| KPV | Inflammation / wound-healing research | No human clinical studies identified by FDA in its 2026 evaluation | FDA staff assessment weighed against 503A-list inclusion; no drug approval |
| BPC-157 | Soft-tissue and gut research | Extremely limited human evidence | Separate FDA 503A/PCAC review; no drug approval |
| TB-500 | Wound / soft-tissue research | Limited and molecule-specific human context | Separate FDA 503A/PCAC review; no TB-500 drug approval |
For the wider evidence hierarchy, see our 7 Research Peptides Compared guide. In addition, you can compare KPV with the MOTS-c evidence & legal-status guide and the GLP-1 medicines comparison .
KPV Peptide FAQ
Is KPV legal in the UK?
KPV is not a UK-licensed medicine. However, UK law allows some unlicensed medicines to be supplied through limited regulated routes for individual clinical need. Readers should not treat “unlicensed” as a simple statement about possession or every possible import scenario.
What is KPV peptide studied for?
Researchers mainly study KPV in preclinical models of inflammation and wound healing, including intestinal and skin-related pathways. FDA’s 2026 evaluation focused on wound healing and inflammatory conditions.
Does KPV have human clinical trial data?
FDA’s 2026 evaluation says that it did not identify clinical studies or human exposure data for KPV free base or KPV acetate by any route. Therefore, the human evidence base remains extremely thin.
Is KPV FDA-approved?
No. KPV is not an FDA-approved medicine. FDA’s 2026 staff evaluation said the available criteria weighed against adding KPV free base or KPV acetate to the 503A Bulks List.
What does KPV have to do with ulcerative colitis?
Researchers have studied KPV in experimental intestinal-inflammation and mouse-colitis models, including work involving the PepT1 transporter. However, that preclinical research does not establish KPV as a treatment for ulcerative colitis in humans.
How does KPV compare with BPC-157 and TB-500?
Writers usually discuss all three as research peptides, but their proposed uses and evidence bases differ. KPV centers more on inflammation and wound-healing research, whereas BPC-157 and TB-500 appear more often in soft-tissue and repair discussions. None should be treated as equivalent to an approved medicine.
Related KPV & Recovery Research Listings
KPV (10mg)
€34.99. The compound discussed in this guide; controlled human treatment evidence remains absent.
BPC-157 (5mg / 10mg / 20mg)
€29.99–€59.99. A separate research peptide frequently compared with KPV in gut and recovery content.
KLOW 80mg
€89.99 — out of stock when checked. Contains KPV, BPC-157, TB-500 and GHK-Cu; single-compound evidence does not validate the blend.
Affiliatevermelding: Supplier links are affiliate links, so PeptideDeepDive may receive a commission. Prices and stock reflect shop data checked on 18 September 2026 and may change. Listings are for laboratory research only.
Bronnen
- Amerikaanse geneesmiddelenautoriteit FDA (2026) FDA Evaluation of KPV-Related Bulk Drug Substances — 2026 briefing document on KPV free base and KPV acetate.
- Amerikaanse geneesmiddelenautoriteit FDA (2026) July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting — KPV-related bulk substances were discussed on July 23.
- U.S. Food and Drug Administration, Certain bulk drug substances that may present significant safety risks — FDA states that it has not identified human exposure data for drug products containing KPV by any route.
- Dalmasso, G. et al. (2008), PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation , Gastroenterology — human cell-line and mouse-colitis research.
- Pawar, K. et al. (2017), Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin , Journal of Pharmaceutical Sciences — ex-vivo human skin delivery study.
- Medicines and Healthcare products Regulatory Agency (MHRA), Supply unlicensed medicinal products (specials) — UK rules for unlicensed medicines.
- Health Products Regulatory Authority (HPRA), Find an authorised medicine — Irish regulator medicines search and guidance.
- European Union, Directive 2001/83/EC on medicinal products for human use — EU marketing-authorisation framework.
KPV Peptide: Evidence, Safety & Legal Status
KPV is a three-amino-acid peptide fragment studied mainly in preclinical inflammation, gut and skin models. Human treatment evidence remains absent, so this guide separates laboratory findings from what is actually known about safety, FDA status and UK/EU regulation.
KPV (lysine-proline-valine) is a three-amino-acid peptide fragment of α-melanocyte-stimulating hormone studied for anti-inflammatory effects. Most evidence comes from cell and animal models involving intestinal or skin inflammation. FDA’s 2026 review found no human clinical studies or human exposure data for KPV, and KPV is not an FDA-approved medicine.
Het redactieteam van PeptideDeepDive checks evidence claims against primary literature and regulatory claims against FDA, MHRA, HPRA and EU legal sources. We have not added a medical reviewer credential because no verified clinician reviewer was provided. This page is educational only and does not provide dosing, treatment or legal advice.
What Is KPV Peptide?
KPV (lysine-proline-valine) is the C-terminal tripeptide fragment of α-melanocyte-stimulating hormone (α-MSH). Researchers mainly study it for anti-inflammatory effects in intestinal, immune-cell and skin models. However, interest around KPV and ulcerative-colitis-like inflammation comes from laboratory and animal work, not from controlled human treatment trials. For broader recovery-peptide context, compare the evidence with BPC-157 en TB-500 .
The FDA has not approved KPV for any use, and FDA’s 2026 briefing document says that neither KPV free base nor KPV acetate is a component of an FDA-approved drug. Meanwhile, in the UK and EU, the key regulatory issue is different: KPV does not hold a standard medicine marketing authorisation. Therefore, rules on unlicensed supply, import and possession can differ by jurisdiction.
How KPV Is Thought to Work
Preclinical studies suggest that KPV can affect inflammatory signalling, including NF-κB-related pathways, and can enter certain intestinal and immune cells through the PepT1 transporter. For example, a 2008 Gastroenterology study found reduced inflammatory signalling in human cell lines and reduced colitis measures in mouse models. Even so, those findings do not show that KPV treats inflammatory bowel disease or skin disease in people.
What Does the KPV Peptide Evidence Show?
Human clinical evidence is not just limited; FDA’s 2026 evaluation says it did not identify clinical studies or human exposure data for KPV free base or KPV acetate by any route. Instead, the evidence base includes cell studies, animal inflammation models and a human-cadaver-skin delivery study. In the gut literature, KPV has reduced inflammatory signals and colitis measures in experimental models. However, researchers have not established controlled human efficacy.
FDA also reported that it did not identify human pharmacokinetic, pharmacodynamic or exposure studies for KPV. As a result, clinical trials have not established validated human dosing or long-term human safety. Accordingly, this article does not provide dosing guidance.
KPV FDA Status in 2026: Approval, 503A & Safety Gaps
KPV had no FDA drug approval and no applicable USP/NF drug-substance monograph. Originally, sponsors withdrew the bulk-substance nomination. Nevertheless, FDA chose to evaluate KPV free base and KPV acetate on its own initiative.
FDA’s Pharmacy Compounding Advisory Committee discussed KPV-related bulk substances for possible inclusion on the 503A Bulks List. Specifically, FDA evaluated wound healing and inflammatory conditions. Ultimately, the agency’s briefing document said the evaluation criteria weighed against adding KPV free base or KPV acetate to the list. Even so, advisory-committee input is non-binding, and FDA still has to complete its own rulemaking process.
KPV is not FDA-approved. FDA’s 2026 KPV briefing found no applicable USP/NF drug-substance monograph, no FDA-approved drug containing KPV free base or acetate, no human clinical studies, and insufficient effectiveness and safety information for the proposed compounded uses. FDA staff concluded that the available criteria weighed against adding KPV free base or KPV acetate to the 503A Bulks List. Read the FDA KPV briefing document.
FDA’s current compounding-safety page also states that it has not identified human exposure data for drug products containing KPV by any route and therefore lacks important information needed to determine whether KPV could cause harm in people. That is different from preclinical anti-inflammatory findings.
Is KPV Legal in the UK, Ireland, Germany & EU?
KPV does not have the kind of standard medicine marketing authorisation that approved medicines hold in the UK or EU. However, that fact does not create one simple Europe-wide answer about possession or import. Instead, national rules on unlicensed medicinal products, supply and customs can differ. Therefore, the summaries below focus on medicine-authorisation status and do not provide legal advice.
🇬🇧 United Kingdom MHRA
KPV is not a UK-licensed medicine. However, the MHRA allows limited regulated supply of certain unlicensed medicines when a prescriber identifies a special clinical need for an individual patient. That “specials” route does not amount to general KPV approval or permit unrestricted consumer marketing. See the MHRA guidance on unlicensed medicines .
🇮🇪 Ireland HPRA
KPV does not appear as a standard authorised human medicine in the regulatory framework used by HPRA. Irish medicine supply and import rules can differ from simple product-authorisation status, so readers should check current HPRA guidance for a specific situation.
🇩🇪 Germany EU / National Rules
There is no standard EU marketing authorisation for KPV as a medicine. Germany also applies national medicines law to manufacture, supply and import, so the absence of marketing authorisation should not be reduced to a simple “legal/illegal” label.
🇪🇺 European Union Directive 2001/83/EC
EU medicines law generally requires a marketing authorisation before a medicinal product is placed on a member-state market, subject to defined exceptions in national law. KPV has no standard EU medicine authorisation discussed in the sources used for this guide.
The sources reviewed for this guide did not identify a standard EU marketing authorisation for KPV. Likewise, KPV is not a UK-licensed medicine. For that reason, anyone facing a real-world import or supply question should check current regulator guidance and obtain local legal advice rather than relying on a simple “legal” or “illegal” label.
KPV vs BPC-157 & TB-500: How They Compare
| Peptide | Primary research focus | Human evidence | 2026 regulatory note |
|---|---|---|---|
| KPV | Inflammation / wound-healing research | No human clinical studies identified by FDA in its 2026 evaluation | FDA staff assessment weighed against 503A-list inclusion; no drug approval |
| BPC-157 | Soft-tissue and gut research | Extremely limited human evidence | Separate FDA 503A/PCAC review; no drug approval |
| TB-500 | Wound / soft-tissue research | Limited and molecule-specific human context | Separate FDA 503A/PCAC review; no TB-500 drug approval |
For the wider evidence hierarchy, see our 7 Research Peptides Compared guide. In addition, you can compare KPV with the MOTS-c evidence & legal-status guide and the GLP-1 medicines comparison .
KPV Peptide FAQ
Is KPV legal in the UK?
KPV is not a UK-licensed medicine. However, UK law allows some unlicensed medicines to be supplied through limited regulated routes for individual clinical need. Readers should not treat “unlicensed” as a simple statement about possession or every possible import scenario.
What is KPV peptide studied for?
Researchers mainly study KPV in preclinical models of inflammation and wound healing, including intestinal and skin-related pathways. FDA’s 2026 evaluation focused on wound healing and inflammatory conditions.
Does KPV have human clinical trial data?
FDA’s 2026 evaluation says that it did not identify clinical studies or human exposure data for KPV free base or KPV acetate by any route. Therefore, the human evidence base remains extremely thin.
Is KPV FDA-approved?
No. KPV is not an FDA-approved medicine. FDA’s 2026 staff evaluation said the available criteria weighed against adding KPV free base or KPV acetate to the 503A Bulks List.
What does KPV have to do with ulcerative colitis?
Researchers have studied KPV in experimental intestinal-inflammation and mouse-colitis models, including work involving the PepT1 transporter. However, that preclinical research does not establish KPV as a treatment for ulcerative colitis in humans.
How does KPV compare with BPC-157 and TB-500?
Writers usually discuss all three as research peptides, but their proposed uses and evidence bases differ. KPV centers more on inflammation and wound-healing research, whereas BPC-157 and TB-500 appear more often in soft-tissue and repair discussions. None should be treated as equivalent to an approved medicine.
Related KPV & Recovery Research Listings
KPV (10mg)
€34.99. The compound discussed in this guide; controlled human treatment evidence remains absent.
BPC-157 (5mg / 10mg / 20mg)
€29.99–€59.99. A separate research peptide frequently compared with KPV in gut and recovery content.
KLOW 80mg
€89.99 — out of stock when checked. Contains KPV, BPC-157, TB-500 and GHK-Cu; single-compound evidence does not validate the blend.
Affiliatevermelding: Supplier links are affiliate links, so PeptideDeepDive may receive a commission. Prices and stock reflect shop data checked on 18 September 2026 and may change. Listings are for laboratory research only.
Bronnen
- Amerikaanse geneesmiddelenautoriteit FDA (2026) FDA Evaluation of KPV-Related Bulk Drug Substances — 2026 briefing document on KPV free base and KPV acetate.
- Amerikaanse geneesmiddelenautoriteit FDA (2026) July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting — KPV-related bulk substances were discussed on July 23.
- U.S. Food and Drug Administration, Certain bulk drug substances that may present significant safety risks — FDA states that it has not identified human exposure data for drug products containing KPV by any route.
- Dalmasso, G. et al. (2008), PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation , Gastroenterology — human cell-line and mouse-colitis research.
- Pawar, K. et al. (2017), Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin , Journal of Pharmaceutical Sciences — ex-vivo human skin delivery study.
- Medicines and Healthcare products Regulatory Agency (MHRA), Supply unlicensed medicinal products (specials) — UK rules for unlicensed medicines.
- Health Products Regulatory Authority (HPRA), Find an authorised medicine — Irish regulator medicines search and guidance.
- European Union, Directive 2001/83/EC on medicinal products for human use — EU marketing-authorisation framework.